Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner

BTK inhibitor (BTKi) Ibrutinib carries an increased bleeding risk compared to more selective BTKis Acalabrutinib and Zanubrutinib, however, its impact on vascular endothelium remains unknown. In this study, we found that Ibrutinib induced stronger cytotoxic effect on endothelial cells than Zanubruti...

Full description

Bibliographic Details
Main Authors: Jia Liu, Zhuojun Liu, Jing Zhang, Xiaofang Chen, Junge Chen, Linlin Sui, Jian Yu
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Pharmaceutics
Subjects:
Ibrutinib
Acalabrutinib
Zanubrutinib
vascular endothelial dysfunction
angiogenesis inhibitor
Online Access:https://www.mdpi.com/1999-4923/14/9/1876

Similar Items

Similar Items